Study to assess oral therapy for patients with inadequate response to TNF inhibitors More: Elevara begins phase 2b trial of ELV001 in rheumatoid arthritis Source: News
read more
Phase 3 trial delivers significant skin clearance and symptom improvement More: Lebrikizumab shows strong results for children with atopic dermatitis Source: News
read moreWhile BioMarin has been focusing heavily on its CNP analogue, Voxzogo, to write the next chapter of the company’s growth story, a change in its clinical development plans introduces further uncertainty into the company’s calculus. More: BioMarin pumps brakes on
read moreAmgen’s Amjevita, Aimovig and Repatha—plus GSK’s Ellipta inhalers and its Relenza—became available through the government drug platform on Monday. More: Meds from Amgen, GSK now offered through TrumpRx DTC platform Source: fierce
read moreIdorsia is gearing up for another CEO change with the news that Srishti Gupta, M.D., is leaving the company. As the company commences its search for a new CEO, board chair Jean-Paul Clozel, M.D., is taking responsibility for day-to-day operations
read moreWith positive results from a phase 3 trial of Ebglyss, Eli Lilly is set up to make the IL-13 inhibitor available to a younger group of patients with atopic dermatitis. More: Lilly eczema results set up potential expansion of Ebglyss
read more© 1994 - 2026 B.M. Pharmaceuticals